Higher risk of AF with CKD linked to fibroblast growth factor 23

Fibroblast growth factor-23 (FGF-23) is hormone derived from the bone, which rises in chronic kidney disease (CKD) in an attempt to maintain proper phosphate homeostasis. FGF-23 enhances excretion of phosphate in urine and inhibits intestinal absorption of phosphate by reducing the production of 1,25-dihydroxycholecalciferol (1,25-dihydroxyvitamin D3). Analysis of data from The Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS) has shown a link between FG-23 and atrial fibrillation [Mathew JS et al. Fibroblast Growth Factor-23 and Incident Atrial Fibrillation. Circulation. 2014; 130: 298-307]. Higher circulation levels of FGF-23 was associated with new onset of atrial fibrillation. In previous studies, FGF-23 has been linked with cardiovascular disease, heart failure, myocardial infarction and cardiovascular mortality.

Source: Cardiophile MD - July 22, 2014 Category: Cardiology Authors: Prof. Dr. Johnson Francis MD, DM, FACC, FRCP Edin, FRCP London Tags: General Cardiology AF atrial fibrillation Cardiovascular Health Study chronic kidney disease CKD FGF-23 Fibroblast growth factor-23 MESA Multi-Ethnic Study of Atherosclerosis phosphate homeostasis Source Type: blogs